

# Genome Wide Association Study (GWAS) for identifying Genetic markers Linked to Antibiotic Resistance in E. Coli

Sujitha Jesu Ravi<sup>1</sup> and Harish Manoharan<sup>2</sup>

<sup>1</sup>Saveetha Medical College and Hospital Microbiology Department.

<sup>2</sup>Assistant Professor Saveetha Medical College and Hospital.

\*Corresponding Author  
Sujitha Jesu Ravi

## Article History

Received: 21.09.2025

Revised: 30.09.2025

Accepted: 22.10.2025

Published: 12.11.2025


**Abstract:** The emergence and rapid dissemination of antibiotic resistance in *Escherichia coli* (*E. coli*) represent a pressing global health threat, undermining the efficacy of current antimicrobial therapies. *E. coli*, being both a commensal and a pathogenic bacterium, serves as a key model organism for studying resistance mechanisms due to its genetic versatility and clinical importance. Traditional approaches to studying resistance genes have often been limited to known targets, potentially overlooking novel or epistatic contributors. Genome-Wide Association Studies (GWAS) have revolutionized our ability to systematically identify genetic variants, including single nucleotide polymorphisms (SNPs), mobile genetic elements, and regulatory regions, that are statistically linked to antibiotic resistance phenotypes in *E. coli*. This review highlights key GWAS findings, such as associations with mutations in *gyrA*, *parC*, and the acquisition of resistance genes like *bla*CTX-M and *mcr-1*. Moreover, we explore how GWAS integrates with pan-genomics and machine learning to improve our understanding of multidrug resistance. Future implications include the development of predictive biomarkers, enhanced surveillance, and the tailoring of antimicrobial therapies. GWAS, therefore, offers a powerful, unbiased strategy for mapping the genetic architecture of resistance in *E. coli*, with broad potential in clinical microbiology and public health.

**Keywords:** *E. coli*, Antibiotic Resistance, GWAS, Genetic Markers, Multidrug Resistance.

## INTRODUCTION

*Escherichia coli* (*E. coli*) is a gram-negative, facultative anaerobic bacterium that inhabits the gastrointestinal tract of humans and animals as a commensal organism. While most strains are harmless and play beneficial roles in intestinal health, certain pathogenic variants such as enterotoxigenic, enterohemorrhagic, and uropathogenic *E. coli* are responsible for a wide range of infections including urinary tract infections, neonatal meningitis, and severe diarrheal illnesses. Due to its dual nature and adaptability, *E. coli* has become a model organism for studying bacterial physiology, genetics, and pathogenesis.

Over the past decades, the rise of antibiotic resistance in *E. coli* has emerged as a major public health concern. The World Health Organization (WHO) has identified antimicrobial-resistant *E. coli* as a critical priority pathogen, citing its role in causing common yet increasingly difficult-to-treat infections. The prevalence of extended-spectrum  $\beta$ -lactamase (ESBL)-producing and carbapenem-resistant *E. coli* strains has led to higher morbidity, mortality, and healthcare costs globally [1]. Resistance is often driven by both chromosomal mutations and the acquisition of mobile genetic elements, such as plasmids and integrons, which facilitate horizontal gene transfer and accelerate the spread of resistance genes (Figure 1).



**Figure 1: Schematic representation of GWAS for identifying Genetic markers**

In this context, Genome-Wide Association Studies (GWAS) have emerged as a powerful approach to uncovering the genetic basis of antibiotic resistance in bacterial populations. Unlike traditional gene-centric methods, GWAS enables an unbiased, high-throughput investigation of genome-wide variations including single nucleotide polymorphisms (SNPs), structural variations, and accessory genes and their associations with phenotypic traits such as antibiotic resistance. By correlating genetic data with phenotypic profiles across a diverse panel of *E. coli* strains, GWAS can identify novel resistance determinants and elucidate the complex architecture of multidrug resistance [2].

This narrative review aims to provide a comprehensive overview of the application of GWAS in identifying genetic markers linked to antibiotic resistance in *E. coli*. We discuss key resistance mechanisms, the principles and tools of bacterial GWAS, landmark findings from recent studies, and the potential of integrating GWAS with other omics technologies. Furthermore, we examine the clinical and epidemiological implications of these discoveries and highlight future directions for research in this evolving field.

## ANTIBIOTIC RESISTANCE IN E. COLI

Antibiotic resistance in *Escherichia coli* has become a major global health threat, driven by the organism's remarkable genetic plasticity and its ability to acquire and disseminate resistance determinants. The rapid emergence of resistant *E. coli* strains complicates the treatment of common infections, increases patient morbidity and mortality, and places a substantial burden on healthcare systems. Understanding the resistance mechanisms and sources of resistant strains is critical for designing effective surveillance, treatment, and prevention strategies [3].

### 2.1 Common Antibiotics and Resistance Mechanisms

#### *β*-lactams

*E. coli* exhibits resistance to *β*-lactam antibiotics primarily through the production of *β*-lactamases,

enzymes that hydrolyze the *β*-lactam ring and render the drug ineffective. Among these, **Extended-Spectrum *β*-Lactamases (ESBLs)** such as *CTX-M*, *TEM*, and *SHV* are of particular concern due to their ability to inactivate a broad spectrum of cephalosporins and penicillins. Additionally, **carbapenemases** such as *NDM-1*, *KPC*, and *OXA-48* have emerged, conferring resistance to last-resort carbapenem antibiotics and severely limiting therapeutic options [4].

#### Fluoroquinolones

Resistance to fluoroquinolones like ciprofloxacin is commonly mediated by point mutations in the **quinolone resistance-determining regions (QRDRs)** of *gyrA* and *parC*, which encode subunits of DNA gyrase and topoisomerase IV, respectively. These mutations decrease the drugs' binding affinity to their targets. Plasmid-mediated resistance genes, such as *qnr*, further contribute by protecting DNA gyrase from quinolone inhibition.

#### Aminoglycosides

Aminoglycoside resistance in *E. coli* is largely attributed to **aminoglycoside-modifying enzymes (AMEs)**, which enzymatically inactivate the drug through acetylation, phosphorylation, or adenylation. Genes encoding these enzymes, such as *aac(6')-Ib*, *aph(3')-Ia*, and *aadA*, are frequently found on mobile genetic elements and can co-exist with other resistance determinants [5].

### Tetracyclines, Sulfonamides, and Polymyxins

Resistance to **tetracyclines** is primarily due to efflux pumps (e.g., *tetA*, *tetB*) or ribosomal protection proteins that prevent drug binding. **Sulfonamide** resistance is conferred by altered dihydropteroate synthase enzymes encoded by *sul1*, *sul2*, and *sul3*. The emergence of **colistin resistance**, especially via the plasmid-mediated *mcr-1* gene, poses a significant threat as colistin is considered a last-resort antibiotic for multidrug-resistant Gram-negative infections (Table 1).

**Table 1: Common Antibiotic Classes and Resistance Mechanisms in *E. coli***

| Antibiotic Class  | Example Drugs                            | Resistance Mechanisms                  | Key Genetic Markers                                             |
|-------------------|------------------------------------------|----------------------------------------|-----------------------------------------------------------------|
| <i>β</i> -lactams | Penicillins, Cephalosporins, Carbapenems | Production of ESBLs and carbapenemases | <i>blaCTX-M</i> , <i>blaTEM</i> , <i>blaNDM</i> , <i>blaKPC</i> |
| Fluoroquinolones  | Ciprofloxacin, Norfloxacin               | Target site mutations                  | <i>gyrA</i> , <i>parC</i>                                       |
| Aminoglycosides   | Gentamicin, Amikacin                     | Enzymatic modification                 | <i>aac(6')-Ib</i> , <i>aph(3')-Ia</i> , <i>aadA</i>             |
| Tetracyclines     | Doxycycline                              | Efflux pumps, ribosomal protection     | <i>tetA</i> , <i>tetB</i>                                       |
| Sulfonamides      | Sulfamethoxazole                         | Target modification                    | <i>sul1</i> , <i>sul2</i>                                       |
| Polymyxins        | Colistin                                 | Lipid A modification                   | <i>mcr-1</i> , <i>mcr-2</i>                                     |

### 2.2 Clinical and Environmental Sources of Resistant *E. coli*

#### Hospital-Acquired vs. Community-Acquired Strains

Hospital-acquired *E. coli* infections are often associated with multidrug-resistant strains, including ESBL and carbapenemase producers, particularly in intensive care units and immunocompromised patients. These strains are frequently linked to invasive infections such as bloodstream infections and ventilator-associated pneumonia. In contrast, **community-acquired resistant *E. coli*** notably ESBL-producing uropathogenic strains are increasingly reported, blurring the traditional boundaries between hospital and community settings [6].

#### Zoonotic and Waterborne Transmission

Resistant *E. coli* strains have also been isolated from **livestock, poultry, and aquaculture**, suggesting that **antibiotic use in food-producing animals** plays a significant role in the selection and dissemination of resistance genes. Contaminated meat, dairy products, and produce can serve as reservoirs for zoonotic transmission. Additionally, **water sources contaminated with human and animal waste** including sewage, agricultural runoff, and untreated wastewater facilitate environmental transmission and the spread of resistance through aquatic ecosystems (Table 2).

**Table 2: Clinical and Environmental Sources of Resistant *E. coli***

| Source Type             | Description                                  | Notable Features/Examples                    |
|-------------------------|----------------------------------------------|----------------------------------------------|
| Hospital-acquired       | Nosocomial infections in ICU, surgical wards | MDR strains with ESBLs and carbapenemases    |
| Community-acquired      | Infections in non-hospitalized individuals   | UTIs caused by ST131                         |
| Zoonotic transmission   | From livestock, poultry                      | Resistance via food chain and direct contact |
| Waterborne transmission | Contaminated water sources                   | Environmental reservoirs of ARGs             |

### 3. Genome-Wide Association Studies (GWAS): Concept and Application

Genome-Wide Association Studies (GWAS) have revolutionized microbial genomics by enabling the systematic identification of genetic variants associated with specific phenotypes, such as antibiotic resistance. Unlike targeted gene studies, GWAS offers an unbiased, high-throughput approach to uncover both known and novel genetic determinants, including SNPs, gene presence/absence, and mobile genetic elements. In *E. coli*, the application of GWAS has provided critical insights into the complex genetic architecture of antimicrobial resistance, especially in diverse and recombinogenic populations [7].

#### 3.1 Principles of GWAS


##### **Linkage Disequilibrium and SNP Analysis**

GWAS relies on the concept of linkage disequilibrium (LD) the non-random association of alleles at different loci. In bacterial populations, LD can extend over long genomic distances due to clonal reproduction. GWAS identifies single nucleotide polymorphisms (SNPs) and other genetic features that occur more frequently in resistant versus susceptible isolates, suggesting a potential functional role. High-density SNP analysis can reveal both causal mutations and closely linked markers [8].

##### **Phenotype-Genotype Correlation Models**

To establish associations, GWAS employs statistical models that correlate genotype with phenotype. The most commonly used models include:

- Linear and logistic regression models: Suitable for simple traits but can lead to spurious associations in clonal populations.
- Mixed linear models (LMMs): Incorporate kinship or relatedness matrices to control for population structure and genetic background effects, thereby reducing false positives.
- Bayesian models: Used in some tools to integrate prior knowledge and probabilistic inferences (Figure 2).



**Figure 2: GWAS Model range from simple to complex**

### Importance of Population Structure Correction

In bacteria like *E. coli*, where clonal expansion and recombination are common, population stratification can confound GWAS results. Correction for population structure is essential to avoid identifying lineage-associated markers rather than true resistance determinants. This is typically achieved using [9]:

- Principal component analysis (PCA)
- Phylogenetic trees
- Kinship matrices or genomic relationship matrices

### 3.2 Tools and Pipelines for Bacterial GWAS

Several computational tools and pipelines have been developed to perform GWAS in microbial genomes, each with specific strengths and features.

#### SEER (Sequence Element Enrichment Analysis)

SEER is one of the first tools developed for bacterial GWAS. It detects associations between k-mers (short nucleotide sequences) and phenotypes without requiring genome annotation. SEER accounts for population structure using multi-dimensional scaling (MDS) and is effective in identifying SNPs, gene presence/absence, and indels associated with resistance [10]

#### pySEER

An extension of SEER, pySEER integrates improved statistical models, including linear mixed models (LMMs), and supports both k-mer and gene-based inputs. It allows users to incorporate phenotype data, covariates, and relatedness matrices to reduce false positives. pySEER is now widely adopted for bacterial GWAS and supports visualization tools and reproducibility pipelines [11].

#### DBGWAS (De Bruijn Graph GWAS)

DBGWAS uses De Bruijn graph-based representations of genomes to identify SNPs, indels, and structural variants in both core and accessory genomes. It offers graphical interpretation of results, making it particularly useful for complex pan-genome analyses.

#### bugwas

This R-based tool combines core genome phylogeny and population structure correction with efficient SNP analysis. It is suitable for studies focusing on core genome variants and works well with high-quality genome alignments (Table 3).

**Table 3: Popular Tools and Pipelines for Bacterial GWAS**

| Tool/Pipeline | Description                                   | Key Features                                         |
|---------------|-----------------------------------------------|------------------------------------------------------|
| SEER          | Sequence Element Enrichment Analysis          | K-mer based association analysis                     |
| pySEER        | Python-based SEER implementation              | Supports mixed models, corrects population structure |
| DBGWAS        | De Bruijn Graph-based GWAS                    | Detects accessory genome variations                  |
| bugwas        | Bayesian GWAS for bacteria                    | Models lineage structure, SNP associations           |
| ResFinder     | Web tool for detecting known resistance genes | Uses BLAST against curated resistance database       |
| PATRIC        | Bacterial genome database with GWAS tools     | Includes metadata and phenotype integration          |

### 3.3 Databases Supporting GWAS Studies

Several genomic databases support GWAS in *E. coli* by providing access to high-quality genome sequences and annotated resistance determinants [12]:

- PATRIC (Pathosystems Resource Integration Center): Offers integrated tools for genome annotation, comparative analysis, and metadata tracking for clinical isolates.
- NCBI Pathogen Detection: Houses a vast collection of bacterial genome assemblies with resistance profiles linked to epidemiological data.
- ResFinder: A curated database of known antimicrobial resistance genes, useful for validating GWAS findings and identifying gene clusters associated with resistance phenotypes.

## 4. Application of GWAS in Studying *E. coli* Antibiotic Resistance

Genome-Wide Association Studies (GWAS) have transformed the landscape of microbial resistance research by enabling the discovery of both known and novel genetic elements contributing to antibiotic resistance. In *E. coli*, GWAS has been successfully applied to dissect the genetic underpinnings of resistance to various classes of antibiotics and to understand the broader architecture of multidrug resistance (MDR) across diverse strains and lineages [13].

#### 4.1 Identified Resistance Markers from GWAS Studies

##### SNPs in *gyrA*, *parC*, *blaCTX-M*, *mcr*, and *acrB* Genes

GWAS has identified several point mutations (SNPs) that are strongly associated with antibiotic resistance [14]:

- *gyrA* and *parC* mutations in the quinolone resistance-determining regions (QRDRs) have consistently been associated with resistance to fluoroquinolones, such as ciprofloxacin and levofloxacin.
- The *blaCTX-M* gene family encodes extended-spectrum  $\beta$ -lactamases (ESBLs) and is widely distributed among resistant *E. coli* isolates. Variants like *blaCTX-M-15* are particularly prevalent in high-risk clones.
- The *mcr* (mobilized colistin resistance) gene family, especially *mcr-1*, confers plasmid-mediated resistance to colistin, a last-resort antibiotic.
- Mutations in *acrB*, a component of the AcrAB-TolC efflux pump system, have been linked to resistance against multiple antibiotic classes, including  $\beta$ -lactams and fluoroquinolones, by enhancing drug efflux [15].

##### Mobile Genetic Elements: Plasmids, Transposons, Integrons

GWAS has also pinpointed the importance of mobile genetic elements (MGEs) in disseminating resistance:

- Plasmids, such as IncF and IncI1 types, frequently carry resistance determinants like *blaCTX-M*, *aac(6')-Ib*, and *qnr* genes.
- Transposons (e.g., Tn3, Tn21) and integrons (e.g., class 1 integrons) serve as vehicles for horizontal gene transfer, integrating multiple resistance genes into the host genome or plasmid.
- These elements facilitate the spread of resistance across bacterial populations, often in association with selective pressure from antimicrobial usage [16].

##### Regulatory and Intergenic Variants Linked to Resistance Phenotypes

GWAS has begun to uncover non-coding variants, including regulatory SNPs and intergenic regions, that influence gene expression and resistance:

- Mutations in promoter regions upstream of resistance genes can enhance transcriptional activity, increasing antibiotic tolerance.
- Variants in global regulators (e.g., *marR*, *soxS*) can modulate multiple resistance pathways simultaneously [17].
- Intergenic regions may also impact small RNAs (sRNAs) that regulate resistance gene networks (Table 4).

**Table 4: GWAS-Identified Genetic Markers Associated with Resistance in *E. coli***

| Marker Type                | Examples                                        | Associated Resistance Phenotype              |
|----------------------------|-------------------------------------------------|----------------------------------------------|
| SNPs in core genes         | <i>gyrA</i> , <i>parC</i> , <i>acrB</i>         | Fluoroquinolone and efflux pump resistance   |
| $\beta$ -lactamase genes   | <i>blaCTX-M</i> , <i>blaSHV</i> , <i>blaTEM</i> | Extended-spectrum $\beta$ -lactam resistance |
| Colistin resistance genes  | <i>mcr-1</i> , <i>mcr-2</i>                     | Polymyxin resistance                         |
| Intergenic/regulatory SNPs | Upstream of efflux pump or porin genes          | Altered gene expression, MDR phenotypes      |
| Mobile elements            | Integrons, IS elements, plasmids                | Horizontal transfer of multiple ARGs         |

#### 4.2 Multidrug Resistance (MDR) and Pan-Genome-Wide Association

##### GWAS in High-Risk Clones like ST131 and ST1193

GWAS has provided critical insights into the evolution of high-risk clones such as:

- ST131, a globally dominant clone associated with multidrug resistance and extraintestinal infections, often carries ESBL genes (*blaCTX-M*), fluoroquinolone resistance mutations, and virulence-associated genomic islands.
- ST1193, an emerging clone, exhibits similar patterns of fluoroquinolone and cephalosporin resistance. GWAS analyses have linked its resistance profile to specific SNPs in *gyrA*, *parC*, and plasmid-borne determinants [18].

These clones often show co-selection of resistance and virulence genes, making them formidable pathogens in both hospital and community settings.

##### Pan-GWAS in Revealing Accessory Genome Contributions

Beyond core genome analysis, pan-genome-wide association studies (pan-GWAS) allow the inclusion of accessory genes (present in a subset of isolates), which often harbor resistance traits [19]:

- Pan-GWAS can uncover genes unique to resistant subpopulations, such as those involved in efflux, biofilm formation, or metal resistance.
- This approach has revealed that horizontal gene transfer events, including plasmid acquisition and recombination, significantly contribute to the development of MDR phenotypes in *E. coli*.
- For example, pan-GWAS studies have identified clusters of resistance genes within genomic islands that are strongly associated with resistance to third-generation cephalosporins and aminoglycosides (Figure 3).






Figure 3: Multidrug resistance in *E.Coli*

## 5. Challenges and Limitations in Bacterial GWAS

Genome-Wide Association Studies (GWAS) have emerged as a powerful tool in identifying genetic determinants of antibiotic resistance in *E. coli*. However, several biological and methodological challenges can limit the accuracy, reproducibility, and interpretability of GWAS findings in bacterial populations. Understanding these limitations is crucial for designing robust studies and drawing valid conclusions [20].

### 5.1 Horizontal Gene Transfer and Its Confounding Effect

One of the most significant challenges in bacterial GWAS is the frequent occurrence of **horizontal gene transfer (HGT)**. Unlike vertical inheritance in eukaryotes, bacteria can acquire genes from unrelated species through plasmids, transposons, integrons, and bacteriophages. This results in genetic elements, including antibiotic resistance genes, being widely distributed across phylogenetically distinct strains. Such events can introduce spurious associations in GWAS, where linked genes carried on mobile genetic elements appear statistically associated with resistance, even if they are not causally involved. This horizontal movement of genes complicates the interpretation of association results and demands the use of specialized analytical models that account for the non-vertical evolution of bacterial genomes [21].

### 5.2 High Genetic Plasticity and Strain Heterogeneity

*E. coli* exhibits a high degree of **genomic plasticity**, comprising a large and diverse accessory genome alongside its conserved core genome. This heterogeneity across strains can hinder GWAS analysis, as resistance traits may be present in some lineages but absent in others. Additionally, the clonal nature of bacterial reproduction leads to the expansion of dominant clones such as ST131 that can skew GWAS findings if not properly corrected for population structure. As a result, lineage-specific variants may be falsely interpreted as resistance determinants. Furthermore, the dynamic nature of the *E. coli* genome, which allows for gene gain and loss, increases the complexity of associating specific genetic features with resistance phenotypes across diverse populations [22].

### 5.3 Phenotyping Accuracy and Metadata Standardization

The success of any GWAS heavily relies on the **quality of phenotypic data** used to define resistance or susceptibility. In bacterial GWAS, inconsistencies in phenotyping methods such as differences in minimum inhibitory concentration (MIC) cut-offs, variations in susceptibility testing platforms, and manual errors can introduce noise and misclassification. While many studies rely on binary classification (resistant vs. susceptible), this approach may overlook subtle variations in resistance levels that quantitative MIC values could capture. Additionally, **incomplete or inconsistent metadata** such as geographic origin, infection source, or host species reduces the ability to adjust for confounding factors and limits the power of stratified analyses [23]. Establishing standard protocols for phenotyping and metadata collection is essential to ensure reproducibility and comparability across studies.

### 5.4 Computational Limitations and Overfitting Risks

Conducting GWAS on bacterial genomes presents **computational and statistical challenges**, particularly due to the high dimensionality of the data. With thousands of SNPs, gene presence/absence markers, and k-mers to analyze, the risk of false-positive associations increases unless rigorous statistical corrections (e.g., Bonferroni, false discovery rate) are applied. Moreover, when the number of genetic features exceeds the number of isolates, the analysis is prone to **overfitting**, leading to models that may perform well on training data but fail to generalize to new samples. Additionally, incorporating corrections for population structure and relatedness adds further computational burden. As bacterial genome datasets continue to grow, **scalability and efficiency of GWAS pipelines** become critical [24]. Advanced computational tools and high-performance computing infrastructure are increasingly required to handle large-scale analyses efficiently (Table 5).

**Table 5: Challenges and Limitations in Bacterial GWAS**

| Challenge                         | Explanation                                                | Example/Impact                                |
|-----------------------------------|------------------------------------------------------------|-----------------------------------------------|
| Horizontal gene transfer (HGT)    | Confounds lineage-based associations                       | Plasmid-borne ARGs seen in unrelated strains  |
| Genetic plasticity                | High genome variability complicates alignment and analysis | Difficult to define core genome in MDR clones |
| Phenotyping inconsistency         | Variations in susceptibility testing or metadata           | Reduced statistical power                     |
| Overfitting in statistical models | Due to small sample sizes or high-dimensional data         | Risk of false positives                       |
| Population structure bias         | Related strains may bias associations                      | Use of LMMs required for correction           |

## 6. Integration with Other Omics and Bioinformatics Tools

While Genome-Wide Association Studies (GWAS) are instrumental in uncovering genetic variants linked to antibiotic resistance in *E. coli*, they are often limited in establishing causal relationships or functional relevance. To bridge this gap, GWAS findings must be integrated with **multi-omics technologies** and **advanced bioinformatics tools**. Combining genomics with transcriptomics, proteomics, metabolomics, and functional validation platforms enhances the biological interpretation of associations and enables the development of predictive and translational models [25].

### 6.1 Transcriptomics for Expression-Phenotype Correlation

**Transcriptomics**, particularly RNA sequencing (RNA-seq), provides insights into the dynamic changes in gene expression in response to antibiotic stress. Integration of GWAS-identified variants with RNA-seq data helps distinguish between structural gene variations and regulatory elements influencing resistance. For example, overexpression of efflux pump genes (*acrAB-tolC*) or downregulation of porins (*ompF*) can be correlated with specific SNPs or promoter variants. Transcriptomic profiling also assists in identifying transcriptional regulators or non-coding RNAs (e.g., sRNAs) that contribute to resistance phenotypes, adding a layer of functional validation to static genomic data [26].

### 6.2 Proteomics and Metabolomics in Functional Validation

While transcriptomics measures potential gene activity, **proteomics** offers direct evidence of protein expression, localization, and post-translational modifications associated with resistance. Techniques like mass spectrometry-based shotgun proteomics can validate the presence and abundance of resistance proteins, such as  $\beta$ -lactamases or efflux pump components, in clinical isolates. Similarly, **metabolomics** helps profile the biochemical impact of resistance, such as changes in metabolic pathways related to cell wall synthesis, energy production, or stress response. By aligning metabolomic shifts with genetic variants, researchers can better understand how resistance mechanisms affect cellular physiology and bacterial fitness [27].

### 6.3 CRISPR-Based Functional Genomics to Confirm GWAS Hits

GWAS identifies statistical associations, but **functional validation** is crucial to confirm causality. The advent of **CRISPR-based genome editing tools** in bacteria, including CRISPR interference (CRISPRi) and CRISPR-Cas9 knockout systems, enables precise manipulation of candidate genes identified through GWAS. These tools can be used to inactivate or repress specific genes and assess their contribution to antibiotic resistance phenotypes in controlled settings. For example, disrupting a gene predicted to enhance efflux activity or antibiotic target modification can directly validate its functional role. CRISPR tools thus bridge the gap between computational prediction and experimental validation [28].

### 6.4 Machine Learning and Artificial Intelligence in Predictive Modeling

The integration of **machine learning (ML)** and **artificial intelligence (AI)** with GWAS and omics data offers powerful predictive capabilities. ML models can be trained on genomic, transcriptomic, and phenotypic datasets to identify patterns and features that best predict resistance profiles. Algorithms such as random forests, support vector machines (SVM), and deep learning models can handle complex, high-dimensional data and detect nonlinear relationships. In the context of *E. coli*, ML has been used to predict resistance based on SNP patterns, gene presence/absence, and even regulatory signatures.

When integrated with GWAS data, these approaches not only enhance the prediction of resistance phenotypes but also prioritize candidate genes for further investigation (Table 6).

**Table 6: Integration of GWAS with Other Omics**

| Omics Layer         | Methodology                      | Role in Resistance Research                      | Example Application                       |
|---------------------|----------------------------------|--------------------------------------------------|-------------------------------------------|
| Transcriptomics     | RNA-seq                          | Expression levels of resistance genes            | Efflux pump overexpression studies        |
| Proteomics          | Mass spectrometry-based          | Protein abundance and post-translational changes | Confirm functional activity of resistance |
| Metabolomics        | NMR, LC-MS                       | Metabolic adaptations to antibiotic pressure     | Disruption in pathways due to resistance  |
| Functional Genomics | CRISPR-Cas9 knockout/activation  | Validate GWAS hits and gene roles                | Confirm essentiality of resistance genes  |
| AI/ML Integration   | Supervised/unsupervised learning | Predict resistance phenotypes from genotype      | Real-time diagnostic tools                |

**7. Clinical and Epidemiological Implications**

The application of Genome-Wide Association Studies (GWAS) in identifying genetic markers of antibiotic resistance in *E. coli* holds significant promise for clinical microbiology and public health. By uncovering genomic signatures associated with resistance, GWAS contributes not only to our understanding of resistance mechanisms but also to **real-world applications** in diagnostics, surveillance, and treatment strategies [29].

**7.1 Early Detection of Resistance Through Genotyping**

One of the most important clinical applications of GWAS findings is the **early detection of resistance genes** through rapid genotyping. Once specific SNPs, genes, or mobile genetic elements associated with resistance are identified and validated, they can be targeted by molecular diagnostic assays such as PCR, qPCR, or whole genome sequencing (WGS)-based pipelines. This enables **rapid, culture-independent detection** of resistant strains directly from clinical samples, allowing for timely initiation of appropriate therapy. For instance, screening for *bla*CTX-M, *mcr*-1, or fluoroquinolone-resistance-associated *gyrA* mutations in urinary isolates of *E. coli* can guide treatment decisions at the point of care [30].

**7.2 Surveillance of Emerging Resistance Clones**

GWAS, when integrated with population genomics, supports **surveillance of emerging and high-risk clones**. For example, global surveillance programs using GWAS have tracked the evolution of multidrug-resistant *E. coli* lineages such as ST131 and ST1193, helping identify hotspots of resistance gene emergence and transmission routes. GWAS-derived markers can be incorporated into real-time surveillance tools to **monitor the geographic spread and genetic evolution** of resistant clones in clinical and environmental settings. This genomic epidemiology approach is critical for informing infection control policies and public health interventions [31].

**7.3 Informing Empirical Therapy and Antimicrobial Stewardship**

Antibiotic stewardship programs rely on accurate data to guide **empirical therapy decisions**, especially in settings where resistance patterns are rapidly changing. GWAS enhances this by providing molecular insights into local and global resistance trends. Clinicians can use this data to select antibiotics with a lower likelihood of resistance, minimizing the use of broad-spectrum agents and preserving their efficacy. Additionally, genomic data can inform **hospital antibiograms and treatment algorithms**, enabling more precise and evidence-based prescribing practices [32].

**7.4 Potential for Personalized Antimicrobial Treatment**

With the increasing availability of rapid sequencing technologies, there is growing interest in **personalized antimicrobial therapy** tailoring antibiotic selection based on the specific resistance genotype of the infecting organism. GWAS provides a framework for this precision medicine approach by mapping genetic variants that predict resistance or susceptibility to different drug classes. In the near future, integration of GWAS data with electronic health records and clinical decision support systems could enable **individualized treatment regimens**, reducing treatment failures and adverse outcomes (Table 7, Figure 4).

**Table 7: Clinical and Epidemiological Implications of GWAS in E. coli**

| Application Area              | Description                                         | Example Impact                     |
|-------------------------------|-----------------------------------------------------|------------------------------------|
| Early resistance detection    | Identification of predictive genetic markers        | Faster empirical therapy decisions |
| Resistance clone surveillance | Tracking high-risk clones using GWAS markers        | Monitoring ST131, ST410, etc.      |
| Empirical treatment guidance  | Regional resistance prediction through genomic data | Localized antibiotic policies      |






Figure 4: Challenges and Limitations

## 8. Future Perspectives and Research Directions

Genome-Wide Association Studies (GWAS) have significantly advanced our understanding of antibiotic resistance in *Escherichia coli*, yet there remain many untapped opportunities for further exploration. As technology, bioinformatics, and data-sharing initiatives evolve, GWAS is poised to play an even more central role in addressing the global challenge of antimicrobial resistance (AMR). The following emerging directions highlight critical areas for future research [33].

### 8.1 Longitudinal and Global GWAS Studies in *E. coli*

Most current GWAS in *E. coli* are cross-sectional, limiting their ability to capture the temporal dynamics of resistance emergence and evolution. **Longitudinal GWAS**, which involve tracking bacterial genomes over time, can provide insight into how resistance traits are acquired, fixed, or lost within populations. Additionally, **global and multi-center GWAS efforts** are necessary to account for geographic variation in resistance determinants and to identify region-specific genetic markers. This global approach will also help in monitoring the international spread of high-risk clones and mobile resistance elements [34].

### 8.2 GWAS in Metagenomic Samples and Polymicrobial Environments

Traditional GWAS relies on pure bacterial isolates, but real-world infections often occur in **complex microbial communities**, such as the gut microbiome or environmental reservoirs. Applying GWAS to **metagenomic datasets** could help detect resistance genes in unculturable strains and identify associations in polymicrobial infections. This approach will require robust algorithms capable of deconvoluting signals from mixed populations and correlating genotype with resistance phenotype in a community context [35].

### 8.3 Exploring Epistatic Interactions and Polygenic Resistance

Antibiotic resistance is often **polygenic**, involving multiple genes and regulatory pathways that interact in non-linear ways. Future GWAS should explore **epistatic interactions** how the effect of one mutation is influenced by the presence of others. This requires advanced computational models and larger datasets to accurately detect interactions and infer causality. Understanding such genetic interactions may uncover novel resistance

mechanisms that are not evident when genes are studied in isolation [36].

#### 8.4 Bridging Basic Research with Translational Applications

To fully realize the potential of GWAS, findings must be **translated into clinical, diagnostic, and therapeutic tools**. This includes developing rapid diagnostic tests based on GWAS-identified markers, incorporating resistance predictors into electronic health records, and using functional validation (e.g., via CRISPR or transcriptomics) to confirm gene function. Furthermore, linking GWAS results with pharmacokinetic/pharmacodynamic (PK/PD) models and drug development pipelines could foster **precision antimicrobial therapy** and novel drug target discovery [37].

## CONCLUSION

The rise of antibiotic-resistant *Escherichia coli* poses a significant challenge to global public health, necessitating innovative strategies to identify and understand the underlying genetic determinants of resistance. Genome-Wide Association Studies (GWAS) have emerged as a transformative approach, enabling researchers to uncover key resistance-associated markers such as mutations in *gyrA*, *parC*, *blaCTX-M*, and the *mcr* gene family, as well as the involvement of mobile genetic elements like plasmids, integrons, and transposons. GWAS has also highlighted the complex role of intergenic and regulatory variants, broadening our understanding of resistance beyond classical gene-centric perspectives [38].

By facilitating large-scale, unbiased correlation between genotype and phenotype, GWAS has significantly advanced the field of microbial genomics. Its application to *E. coli* has not only revealed the genetic architecture of resistance in high-risk clones like ST131 and ST1193 but also provided new insights into the role of accessory genomes in multidrug resistance [39].

Looking forward, the integration of GWAS with other omics technologies such as transcriptomics, proteomics, and CRISPR-based functional genomics offers a promising avenue to validate findings and unravel the functional consequences of genetic variants. Additionally, incorporating machine learning tools for predictive modeling and clinical decision-making can bridge the gap between genomic research and real-world application.

Ultimately, GWAS serves as a critical foundation for the development of precision medicine approaches in infectious diseases, offering the potential for more accurate diagnostics, targeted antimicrobial therapy, and informed stewardship programs. Continued investment in global surveillance, computational infrastructure, and interdisciplinary collaboration will be key to unlocking

the full potential of GWAS in combating antibiotic resistance in *E. coli* and beyond [40].

## REFERENCES

1. Maunsell FP, Donovan GA. 2009. Mycoplasma bovis infections in young calves. *Vet Clin North Am Food Anim Pract* 25:139-177.
2. Maunsell FP, Woolums AR, Francoz D, Rosenbusch RF, Step DL, Wilson DJ, Janzen ED. 2011. Mycoplasma bovis infections in cattle. *J Vet Intern Med* 25:772-783.
3. Calcutt MJ, Lysnyansky I, Sachse K, Fox LK, Nicholas RAJ, Ayling RD. 2018. Gap analysis of Mycoplasma bovis disease, diagnosis and control: an aid to identify future development requirements. *Transbound Emerg Dis* 65(Suppl 1):91-109.
4. Parker AM, Sheehy PA, Hazelton MS, Bosward KL, House JK. 2018. A review of mycoplasma diagnostics in cattle. *J Vet Intern Med* 32:1241-1252.
5. Gautier-Bouchardon AV. 2018. Antimicrobial resistance in Mycoplasma spp. *Microbiol Spectr* 6:ARBA-0030-2018.
6. Gautier-Bouchardon AV, Ferré S, Le Grand D, Paoli A, Gay E, Poumarat F. 2014. Overall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France. *PLoS One* 9:e87672.
7. Lysnyansky I, Ayling RD. 2016. Mycoplasma bovis: mechanisms of resistance and trends in antimicrobial susceptibility. *Front Microbiol* 7:595.
8. Cai HY, McDowall R, Parker L, Kaufman EI, Caswell JL. 2019. Changes in antimicrobial susceptibility profiles of Mycoplasma bovis over time. *Can J Vet Res* 83:34-41.
9. Klein U, de Jong A, Youala M, El Garch F, Stevenin C, Moyaert H, Rose M, Catania S, Gyuranecz M, Pridmore A, Ayling RD. 2019. New antimicrobial susceptibility data from monitoring of Mycoplasma bovis isolated in Europe. *Vet Microbiol* 238:108432.
10. García-Galán A, Nouvel LX, Baranowski E, Gómez-Martín Á, Sánchez A, Citti C, de la Fe C. 2020. Mycoplasma bovis in Spanish cattle herds: two groups of multiresistant isolates predominate, with one remaining susceptible to fluoroquinolones. *Pathogens* 9:545.
11. Liu Y, Xu S, Li M, Zhou M, Huo W, Gao J, Liu G, Kastelic JP, Han B. 2020. Molecular characteristics and antibiotic susceptibility profiles of Mycoplasma bovis associated with mastitis on dairy farms in China. *Prev Vet Med* 182:105106.
12. Bokma J, Gille L, De Blecker K, Callens J, Haesebrouck F, Pardon B, Boyen F. 2020. Antimicrobial susceptibility of Mycoplasma bovis isolates from veal, dairy and beef herds. *Antibiotics* 9:882. doi:10.3390/antibiotics9120882.
13. Kinnear A, McAllister TA, Zaheer R, Waldner M, Ruzzini AC, Andrés-Lasheras S, Parker S, Hill JE, Jelinski MD. 2020. Investigation of macrolide

- resistance genotypes in *Mycoplasma bovis* isolates from Canadian feedlot cattle. *Pathogens* 9:622. doi:10.3390/pathogens9080622.
14. Kong LC, Gao D, Jia BY, Wang Z, Gao YH, Pei ZH, Liu SM, Xin JQ, Ma HX. 2016. Antimicrobial susceptibility and molecular characterization of macrolide resistance of *Mycoplasma bovis* isolates from multiple provinces in China. *J Vet Med Sci* 78:293–296. doi:10.1292/jvms.15-0304.
15. Sulyok KM, Bekő K, Kreizinger Z, Wehmann E, Jerzsele Á, Rónai Z, Turcsányi I, Makrai L, Szeredi L, Jánosi S, Nagy SÁ, Gyuranecz M. 2018. Development of molecular methods for the rapid detection of antibiotic susceptibility of *Mycoplasma bovis*. *Vet Microbiol* 213:47-57.
16. Pereyre S, Goret J, Bébér C. 2016. *Mycoplasma pneumoniae*: current knowledge on macrolide resistance and treatment. *Front Microbiol* 7:974. doi:10.3389/fmicb.2016.00974.
17. Ledger L, Eidt J, Cai HY. 2020. Identification of antimicrobial resistance-associated genes through whole genome sequencing of *Mycoplasma bovis* isolates with different antimicrobial resistances. *Pathogens* 9:588.
18. Jaillard M, Lima L, Tournoud M, Mahé P, van Belkum A, Lacroix V, Jacob L. 2018. A fast and agnostic method for bacterial genome-wide association studies: bridging the gap between k-mers and genetic events. *PLoS Genet* 14:e1007758.
19. Razin S, Yogev D, Naot Y. 1998. Molecular biology and pathogenicity of *Mycoplasmas*. *Microbiol Mol Biol Rev* 62:1094-1156.
20. Vereecke N, Bokma J, Haesebrouck F, Nauwynck H, Boyen F, Pardon B, Theuns S. 2020. High quality genome assemblies of *Mycoplasma bovis* using a taxon-specific Bonito basecaller for MinION and Flongle long-read Nanopore sequencing. *BMC Bioinformatics* 21:517.
21. Bokma J, Vereecke N, De Bleeker K, Callens J, Ribbens S, Nauwynck H, Haesebrouck F, Theuns S, Boyen F, Pardon B. 2020. Phylogenomic analysis of *Mycoplasma bovis* from Belgian veal, dairy and beef herds. *Vet Res* 51:121.
22. World Health Organization. 2017. WHO guidelines on use of medically important antimicrobials in food-producing animals. World Health Organization, Geneva, Switzerland.
23. World Organization for Animal Health. 2019. OIE list of antimicrobial agents of veterinary importance. World Organization for Animal Health, Paris, France.
24. Lysnyansky I, Mikula I, Gerchman I, Levisohn S. 2009. Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in *Mycoplasma bovis*. *Antimicrob Agents Chemother* 53:4911-4914.
25. Sulyok KM, Kreizinger Z, Wehmann E, Lysnyansky I, Bányai K, Marton S, Jerzsele A, Rónai Z, Turcsányi I, Makrai L, Jánosi S, Nagy SÁ, Gyuranecz M. 2017. Mutations associated with decreased susceptibility to seven antimicrobial families in field and laboratory-derived *Mycoplasma bovis* strains. *Antimicrob Agents Chemother* 61:e01983-16.
26. Hata E, Harada T, Itoh M. 2019. Relationship between antimicrobial susceptibility and multilocus sequence type of *Mycoplasma bovis* isolates and development of a method for rapid detection of point mutations involved in decreased susceptibility to macrolides, lincosamides, tetracyclines. *Appl Environ Microbiol* 85:e00575-19.
27. Sato T, Okubo T, Usui M, Higuchi H, Tamura Y. 2013. Amino acid substitutions in gyrA and parC are associated with fluoroquinolone resistance in *Mycoplasma bovis* isolates from Japanese dairy calves. *J Vet Med Sci* 75:1063-1065.
28. Lysnyansky I, Gerchman I, Mikula I, Gobbo F, Catania S, Levisohn S. 2013. Molecular characterization of acquired enrofloxacin resistance in *Mycoplasma synoviae* field isolates. *Antimicrob Agents Chemother* 57:3072-3077.
29. Tatay-Dualde J, Prats-van der Ham M, de la Fe C, Paterna A, Sánchez A, Corrales JC, Contreras A, Gómez-Martín Á. 2017. Mutations in the quinolone resistance determining region conferring resistance to fluoroquinolones in *Mycoplasma agalactiae*. *Vet Microbiol* 207:63-68.
30. Khalil D, Becker CAM, Tardy F. 2016. Alterations in the quinolone resistance-determining regions and fluoroquinolone resistance in clinical isolates and laboratory-derived mutants of *Mycoplasma bovis*: not all genotypes may be equal. *Appl Environ Microbiol* 82:1060-1068.
31. Raherison S, Gonzalez P, Renaudin H, Charron A, Bébér C, Bébér CM. 2002. Evidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by *Mycoplasma hominis*. *Antimicrob Agents Chemother* 46:672-679.
32. Faucher M, Nouvel LX, Dordet-Frisoni E, Sagné E, Baranowski E, Hygonenq MC, Marendia MS, Tardy F, Citti C. 2019. *Mycoplasmas* under experimental antimicrobial selection: the unpredicted contribution of horizontal chromosomal transfer. *PLoS Genet* 15:e1007910.
33. Sato T, Higuchi H, Yokota SI, Tamura Y. 2017. *Mycoplasma bovis* isolates from dairy calves in Japan have less susceptibility than a reference strain to all approved macrolides associated with a point mutation (G748A) combined with multiple species-specific nucleotide alterations in 23S rRNA. *Microbiol Immunol* 61:215-224.
34. Lerner U, Amram E, Ayling RD, Mikula I, Gerchman I, Harrus S, Teff D, Yogev D, Lysnyansky I. 2014. Acquired resistance to the 16-membered macrolides tylosin and tilmicosin by *Mycoplasma bovis*. *Vet Microbiol* 168:365-371.
35. Khalil D, Becker CAM, Tardy F. 2017. Monitoring the decrease in susceptibility to ribosomal RNAs targeting antimicrobials and its molecular basis in

- clinical *Mycoplasma bovis* isolates over time. *Microb Drug Resist* 23:799-811.
36. Liu M, Douthwaite S. 2002. Resistance to the macrolide antibiotic tylosin is conferred by single methylations at 23S rRNA nucleotides G748 and A2058 acting in synergy. *Proc Natl Acad Sci USA* 99:14658-14663.
  37. Citti C, Dordet-Frisoni E, Nouvel LX, Kuo CH, Baranowski E. 2018. Horizontal gene transfers in mycoplasmas (Mollicutes). *Curr Issues Mol Biol* 29:3-22.
  38. Li SL, Sun HM, Zhu BL, Liu F, Zhao HQ. 2017. Whole genome analysis reveals new insights into macrolide resistance in *Mycoplasma pneumoniae*. *Biomed Environ Sci* 30:343-350.
  39. Prats-van der Ham M, Tatay-Dualde J, Gómez-Martín Á, Corrales JC, Contreras A, Sánchez A, de la Fe C. 2018. 23S rRNA and L22 ribosomal protein are involved in the acquisition of macrolide and lincosamide resistance in *Mycoplasma capricolum* subsp. *capricolum*. *Vet Microbiol* 216:207-211.
  40. Amram E, Mikula I, Schnee C, Ayling RD, Nicholas RAJ, Rosales RS, Harrus S, Lysnyansky I. 2015. 16S rRNA gene mutations associated with decreased susceptibility to tetracycline in *Mycoplasma bovis*. *Antimicrob Agents Chemother* 59:796-802.